Introduction: High-dose therapy with AutoHCT is a standard component of therapy for many patients with Hodgkin (HL) and non-Hodgkin lymphoma (NHL). IPS is a known toxicity of AutoHCT which can cause significant morbidity and mortality. The most common agent associated with IPS has traditionally been high-dose BCNU (carmustine). Data on incidence of IPS in recent era and its relation with conditioning regimens are scarce. Methods and Patients: Using the Center for International Bone Marrow Transplant Registry (CIBMTR), we studied 4,573 patients with lymphoma who underwent AutoHCT from 1995-2008 using the following conditioning regimens: BEAM (n¼1730), CBV low (n¼1249), CBV high (n¼604), BuCy (n¼789), and CyTBI (n¼545). We investigated the reported incidence of and explored clinical risk factors for its development, including the dose of BCNU and its impact on outcome (above vs. below 375 mg/m 2 in CBV regimens). We then analyzed the impact of IPS on outcomes including transplant-related mortality (TRM), progression-free survival (PFS), and overall survival (OS). Use of different regimens was as follows: Results: The incidence of IPS by 1 year after AutoHCT was: BEAM (3%), CBV low (3%, HR The importance of optimal long term engraftment after autologous stem cell transplantation is uncertain. We conducted a retrospective analysis of long term engraftment in patients who underwent autologous peripheral blood stem cell transplant for non-Hodgkin lymphoma, Hodgkin lymphoma or multiple myeloma. Patients who relapsed or died prior to assessment of long term engraftment at 1 year were excluded. Optimal engraftment was defined by NCI CTCAE grade 1 criteria for cytopenias (ANC ! 1500/ml, platelets ! 75000/ml, hemoglobin ! 10g/dL). 225 patients were identified with engraftment data at 1 year (92 NHL, 62 HL, 71 MM). The median follow-up was 5.0 years for all patients (5.5 for living patients). 88% of patients achieved optimal engraftment at 1 year. The median cell dose was 4.7 x10 ˇ 6 CD34+ cells/kg, and our institutional minimum cell dose is 2 x10 ˇ 6 CD34+ cells/ kg. CD34 cell dose ! 3 x10 ˇ 6 CD34+ cells/kg and age < 60 were predictive for optimal long term engraftment. Disease type, gender, number of prior therapies and prior radiation therapy were not predictive of achieving long term engraftment. By landmark analysis at 1 year, optimal engraftment was not predictive for progression free survival or overall survival in all patients, although there was a trend for worse outcome with poor engraftment in HL and NHL. Incomplete long term engraftment after autologous transplant is relatively rare with the most important predictors identified as CD34 cell dose and age. For those patients who survive one year, PFS and OS are not diminished afterward.
